Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain
Latest Information Update: 10 Oct 2023
Price :
$35 *
At a glance
- Drugs LY 3526318 (Primary)
- Indications Back pain
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Jul 2022 Status changed from recruiting to completed.
- 06 Apr 2022 Planned End Date changed from 1 Jul 2022 to 17 Jun 2022.
- 06 Apr 2022 Planned primary completion date changed from 1 Jul 2022 to 17 Jun 2022.